Emerging therapies in gastrointestinal cancers.
Members of the receptor tyrosine kinase family, that include EGFR, ErbB-2/HER-2, ErbB-3/HER-3 and ErbB-4/HER-4, are frequently implicated in experimental models of epithelial cell neoplasia as well as in human cancers. Therefore, interference with the activation of these growth factor receptors represents a promising strategy for development of novel and selective anticancer therapies. Indeed, a number of inhibitors that target either EGFR or HER-2, with the exception of a few that target both; have been developed for treatment of epithelial cancers. Since most solid tumors express different ErbB receptors and/or their ligands, identification of inhibitor(s), targeting multiple EGFR family members may provide a therapeutic benefit to a broader patient population. Here we describe the significance of an ErbB family of receptors in epithelial cancers, and summarize different available therapeutics targeting these receptors. It also emphasizes the need to develop pan-ErbB inhibitors and discusses EGF-Receptor Related Protein, a recently isolated negative regulator of EGFR as a potential pan-ErbB therapeutic for a wide variety of epithelial cancers.
Nautiyal
Jyoti
J
Karmanos Cancer Institute, Detroit, MI 48201, United States.
Rishi
Arun K
AK
Majumdar
Adhip P N
AP
D000818:Animals; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000502:physiology; D005770:Gastrointestinal Neoplasms / Q000503:physiopathology / Q000628:therapy*; D006023:Glycoproteins / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D018739:Oncogene Proteins v-erbB / Q000037:antagonists & inhibitors / Q000502:physiology; D011994:Recombinant Proteins / Q000494:pharmacology; D015398:Signal Transduction
D006023:Glycoproteins; D018739:Oncogene Proteins v-erbB; D011994:Recombinant Proteins; C512478:EGFR protein, human; D066246:ErbB Receptors